Analysis of the Microenvironment of Lung Cancer and Exploration of the Mechanism of Resistance to Immunotherapy

The investigators plan to conduct a multiomics analysis（such as, Genomics, proteomics, single cell RNA sequencing, space transcriptomics）of tumor tissue and blood, aiming at analyzing tumor heterogeneity, mapping the microenvironment map of lung cancer and exploring the mechanism of sensitivity and resistance to anti-PD1/PD-L1 antibodies.

Inclusion Criteria:Histopathology or hemology diagnostics of lung cancerPatients have never received any antineoplastic therapyExclusion Criteria:Within 5 years or at the same time, there are other active malignanciesCurrently participating in interventional clinical research treatment, or received other research drugs or used research devices within 4 weeks before the first administrationActive autoimmune diseases requiring systemic treatment (such as the use of disease relieving drugs, glucocorticoids or immunosuppressants) occurred within 2 years before the first administrationThe study was receiving systemic glucocorticoid treatment (excluding local glucocorticoids by nasal spray, inhalation or other means) or any other form of immunosuppressive therapy within 7 days before the first administration; Note: It is allowed to use glucocorticoid with physiological dose (prednisone ≤ 10mg/day or equivalent)Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation